Opportunity Knocks as Mayne Pharma Makes A Transformational Acquisition
Mayne Pharma has agreed to buy a portfolio of U.S. generic products from Teva and Allergan for USD 652 million (AUD 881 million) in cash, primarily...
157 Views
Equity Best Ideas
The Best Ideas list is a compilation of stock ideas sourced from Morningstar’s global equity research team. Recent Asian additions: Allergan...
194 Views
Mayne Pharma Focuses on Building Brand and Maintaining Momentum for Doryx
Notwithstanding Mayne's significant investment already made and planned in United States manufacturing capacity, we have a positive outlook on the...
305 Views
Taxing Times For Australia
The Government's release of Re:think, its tax discussion paper, is a welcome development, designed to kick-start the conversation with the...
5.7k Views